Skip to main content
SpringerLink
Log in

Comment On: “Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study”

  • Letter to the Editor
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lee YR, Palmere PJ, Burton CE, Benavides TM. Stratifying therapeutic enoxaparin dose in morbidly obese patients by BMI class: a retrospective cohort study. Clin Drug Investig. 2019. https://doi.org/10.1007/s40261-019-00855-9.

    Article  PubMed  Google Scholar 

  2. van Oosterom N, Winckel K, Barras M. Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. J Thromb Thromb. 2019;48(3):387–93. https://doi.org/10.1007/s11239-019-01847-4.

    Article  CAS  Google Scholar 

  3. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 2001;119(1):344S–70S. https://doi.org/10.1378/chest.119.1_suppl.344S.

    Article  CAS  PubMed  Google Scholar 

  4. Barras AM, Duffull BS, Atherton JJ, Green JB. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. Ther Drug Monit. 2010;32(4):482–8. https://doi.org/10.1097/FTD.0b013e3181e64846.

    Article  CAS  PubMed  Google Scholar 

  5. Antman EM. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A 11A list of the participating investigators and clinical centers for the TIMI 11A trial appears in the Appendix A. J Am Coll Cardiol. 1997;29(7):1474–82. https://doi.org/10.1016/S0735-1097(97)00094-6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD, 4102, Australia

    Nameer van Oosterom, Karl Winckel & Michael Barras

  2. The University of Queensland, Brisbane, Australia

    Nameer van Oosterom, Karl Winckel & Michael Barras

Authors
  1. Nameer van Oosterom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl Winckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Barras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nameer van Oosterom.

Ethics declarations

Funding

The authors declare that no sources of funding were obtained for this letter.

Conflict of interest

The authors declare that there are no conflicts of interests to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Oosterom, N., Winckel, K. & Barras, M. Comment On: “Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study”. Clin Drug Investig 40, 287–288 (2020). https://doi.org/10.1007/s40261-020-00889-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-020-00889-4

Search

Navigation